Lunit and Summit to evaluate pathology platform for tumour analysis
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing…
26 Oct 2026
Pathos AI completes $237m Series E round to expand oncology pipeline
Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its AI drug development platform. The transaction values the US-based biotechnology…
26 Oct 2026
UK biotech poised for record VC year after maintaining recovery momentum
A new report released by the BioIndustry Association (BIA) has found that the UK is likely on track to post its best year since 2021 for biotech venture capital (VC)…
23 Oct 2026
US targets Chinese biotech investment, but licensing deals remain exempt
The US government is seeking to curb American investment in Chinese firms involved in advanced drug development after adding the biotechnology sector to its list of sensitive technologies. The addition…
23 Oct 2026
Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 receptor inhibitor, which the company hopes will rival Johnson &…
23 Oct 2026
Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have entered a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health. The partnership focuses on evaluating digital…
23 Oct 2026
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m). The financial package…